



RESEARCH ARTICLE

Knockdown of Laminin gamma-3 (*Lamc3*) impairs motoneuron guidance in the zebrafish embryo [version 1; peer review: 2 approved, 2 approved with reservations]

Alexander M. J. Eve , James C. Smith

Developmental Biology Laboratory, Francis Crick Institute, London, NW1 1AT, UK

v1 First published: 16 Nov 2017, 2:111 (<https://doi.org/10.12688/wellcomeopenres.12394.1>)

Latest published: 16 Nov 2017, 2:111 (<https://doi.org/10.12688/wellcomeopenres.12394.1>)

Abstract

Background: Previous work in the zebrafish embryo has shown that laminin γ -3 (*lamc3*) is enriched in endothelial cells marked by expression of *fli1a*, but the role of *Lamc3* has been unknown.

Methods: We use antisense morpholino oligonucleotides, and CRISPR/Cas9 mutagenesis of F0 embryos, to create zebrafish embryos in which *lamc3* expression is compromised. Transgenic imaging, immunofluorescence, and *in situ* hybridisation reveal that *Lamc3* loss-of-function affects the development of muscle pioneers, endothelial cells, and motoneurons.

Results: *Lamc3* is enriched in endothelial cells during zebrafish development, but it is also expressed by other tissues. Depletion of *Lamc3* by use of antisense morpholino oligonucleotides perturbs formation of the parachordal chain and subsequently the thoracic duct, but *Lamc3* is not required for sprouting of the cardinal vein. F0 embryos in which *lamc3* expression is perturbed by a CRISPR/Cas9 approach also fail to form a parachordal chain, but we were unable to establish a stable *lamc3* null line. *Lamc3* is dispensable for muscle pioneer specification and for the expression of *netrin-1a* in these cells. *Lamc3* knockdown causes *netrin-1a* up-regulation in the neural tube and there is increased Netrin-1 protein throughout the trunk of the embryo. Axonal guidance of rostral primary motoneurons is defective in *Lamc3* knockdown embryos.

Conclusions: We suggest that knockdown of *Lamc3* perturbs migration of rostral primary motoneurons at the level of the horizontal myoseptum, indicating that laminin γ 3 plays a role in motoneuron guidance.

Keywords

axon, guidance, migration, motoneuron, netrin, parachordal chain

Open Peer Review

Reviewer Status ? ✓ ✓ ?

	Invited Reviewers			
	1	2	3	4
version 1	?	✓	✓	?
16 Nov 2017	report	report	report	report

- 1 Timothy J.A. Chico, University of Sheffield, Sheffield, UK
- 2 Dong Liu , Nantong University, Nantong, China
- 3 Nicola Facchinello , University of Padova, Padova, Italy
- 4 Thomas A. Hawkins , University College London, London, UK

Any reports and responses or comments on the article can be found at the end of the article.



This article is included in the [The Francis Crick Institute](#) gateway.

Corresponding author: James C. Smith (jim.smith@crick.ac.uk)

Author roles: **Eve AMJ:** Conceptualization, Formal Analysis, Investigation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Smith JC:** Conceptualization, Funding Acquisition, Project Administration, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Wellcome Trust [FC001157]; Cancer Research UK [FC001157]; the UK Medical Research Council [FC001157] and Fondation Leducq.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Eve AMJ and Smith JC. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Eve AMJ and Smith JC. **Knockdown of Laminin gamma-3 (Lamc3) impairs motoneuron guidance in the zebrafish embryo [version 1; peer review: 2 approved, 2 approved with reservations]** Wellcome Open Research 2017, 2:111 (<https://doi.org/10.12688/wellcomeopenres.12394.1>)

First published: 16 Nov 2017, 2:111 (<https://doi.org/10.12688/wellcomeopenres.12394.1>)

Introduction

The zebrafish (*Danio rerio*) is a powerful model for studying the formation of the vascular system. It is well suited to live imaging due to its transparency and external fertilisation. Development is rapid, with functional circulation established within a day of fertilisation (Stainier & Fishman, 1994). Zebrafish are amenable to genetic, cellular, and molecular studies, and many important features of vasculogenesis are conserved with other organisms, including mammals (Baldessari & Mione, 2008; Jing & Zon, 2011). For these reasons, zebrafish studies have already contributed to our understanding of blood and vascular development, often with relevance for human health and disease (Bertrand *et al.*, 2010; Herbert *et al.*, 2009; Wiley *et al.*, 2011).

Several attempts have been made to define the transcriptomes of haematopoietic and vascular precursors in the zebrafish, including the comparison of wild type and vascular deficient cloche mutants by microarray (Stainier *et al.*, 1995; Sumanas *et al.*, 2005). The development of fluorescent transgenic zebrafish lines has made it possible to use fluorescence-activated cell sorting (FACS) of dissociated embryos to achieve such comparisons. The vascular reporter line Tg(*flila*:egfp) has frequently been used in this approach, coupled with both microarray analysis and high throughput RNA sequencing (Lawson & Weinstein, 2002). Such work has demonstrated the enrichment of known blood and endothelial cell-specific transcripts such as *flila*, *tiel*, *scl*, *mpx*, and *gata1* from GFP positive (GFP+) cells compared with gfp negative cells (Cannon *et al.*, 2013; Covassin *et al.*, 2006). High throughput RNA sequencing has also revealed 388 novel transcripts enriched in zebrafish *flila* expressing cells between 26 and 28 hours post fertilisation (hpf), compared with the rest of the embryo (Cannon *et al.*, 2013). Following an unbiased morpholino knockdown approach to assess the importance of these novel transcripts in zebrafish angiogenesis, we focussed on loss-of-function analyses of the *lamc3* (ENSDARG00000060396) gene, which encodes the zebrafish laminin $\gamma 3$ protein.

Laminins are secreted heterotrimeric glycoproteins comprising α , β , and γ chain subunits, with multiple isoforms that self-assemble in a coiled-coil configuration. Out of more than 60 possible combinations, 16 different laminin isoforms have been described (Aumailley *et al.*, 2005; Libby *et al.*, 2000). Both mammals and zebrafish have five α chain isoforms named LAMA1-5. Humans (*Homo sapiens*) have four laminin β chain isoforms (LAMB1-4), mice (*Mus musculus*) have three β chain isoforms (LAMB1-3), and zebrafish have six laminin β genes: *lamb1*, *lamb1b*, *lamb2*, *lamb2l*, *lamb3*, and *lamb4*. In both zebrafish and mammals there are three γ chain isoforms (LAMC1-3) (Domogatskaya *et al.*, 2012).

Laminins form a major part of basement membranes, along with other proteins such as type IV collagens, perlecan, and nidogens. The laminins are involved in processes such as differentiation, migration, adhesion, and tissue organisation, as well as direct communication with cells through binding of cell surface receptors such as integrins and dystroglycans (Domogatskaya *et al.*, 2012; Durbeek *et al.*, 1998; Hallmann *et al.*, 2005). Laminins are required for many embryonic processes including development of the

nervous system, muscle, and vascular system (Miner *et al.*, 1998; Relan *et al.*, 1999). In angiogenesis, laminins have been implicated in vessel formation, vessel stability, and endothelial tip cell specification through integrin-mediated Notch signalling (Hallmann *et al.*, 2005; Kitajewski, 2011; Stenzel *et al.*, 2011).

There are three laminin zebrafish mutants with reported defects in angiogenesis: *bashful* (*bal*), *grumpy* (*gup*), and *sleepy* (*sly*), which encode the laminin $\alpha 1$, $\beta 1$, and $\gamma 1$ proteins respectively (Pollard *et al.*, 2006). The laminin $\gamma 3$ chain is most similar in structure to $\gamma 1$, but is less widely expressed. Laminin $\gamma 3$ has been studied in murine basement membranes as a regulator of retinal neuronal guidance, but there has been no reported investigation into zebrafish Lamc3 (Dénes *et al.*, 2007; Gersdorff *et al.*, 2005; Koch *et al.*, 1999).

Here we use morpholino oligonucleotides and CRISPR/Cas9 mutagenesis of F0 embryos to characterise the consequences of laminin $\gamma 3$ knockdown during development of the zebrafish trunk. We show that embryos lacking Lamc3 fail to form the parachordal chain (PAC) vasculature and that loss of the PAC is an indirect effect, caused by the failure of rostral primary motoneurons to extend at the level of the horizontal myoseptum (Lim *et al.*, 2011). This failure might be explained by the increased expression and mis-localisation of Netrin-1 observed in Lamc3 knockdown embryos.

Methods

Ethics statement

All zebrafish work was carried out with approval from the Francis Crick Institute Biological Research Facility Strategic Oversight Committee and the Animal Welfare and Ethical Review Body, and in accordance with the Animals (Scientific Procedures) Act 1986, the Animal Welfare Act (2006) and the Welfare of Animals in Transport Order. Care was taken to minimize the number of animals used in these experiments, in accordance with the ARRIVE guidelines.

Protein alignments and phylogenetic trees

LAMC1 and LAMC3 amino acid sequences for human (*Homo sapiens*), mouse (*Mus musculus*), and zebrafish (*Danio rerio*) were aligned using MUSCLE. Full length alignments were represented as a barcode with RasMol colouring using Geneious software (Kearse *et al.*, 2012). For phylogenetic trees, the Lamc1-like protein from *Nematostella vectensis* was included as an out-group for the bilaterians and LAMC2 sequences for human, mouse and zebrafish are included (Supplementary data repository, File 1). Aligned sequences were trimmed by eye (Supplementary data repository, File 2) within JalView software and were used for generating a JTT+Gamma model phylogenetic tree using the CIPRES gateway RaxML tool with rapid (100) bootstrapping (Miller *et al.*, 2010; Waterhouse *et al.*, 2009). The generated tree was then presented using FigTree version 1.4.3 and labelled using Adobe Illustrator (Rambaut, 2009).

Quantitative RT-PCR

cDNA from 26 hpf FACS sorted Tg(*flila*:egfp) embryos was a kind gift from Elsie Place (Francis Crick Institute, London, UK),

extracted as previously described (Cannon *et al.*, 2013). Quantitative RT-PCR was performed in duplicate using 10 µl reactions containing 2.5 µl of cDNA (diluted 1:10), 1× SYBR green Mastermix (Roche), and the following primers at 0.5 mM: Lamc3 Fw: 5'-GAGAACCTCTGCCACTCAGG-3'; Lamc3 Rv: 5'-CTCAA GGTGAAACGTCCCAT-3'; *eflα* Fw: 5'-AAGCCCTCAGTGG AGAATGC-3'; *eflα* Rv: 5'-TTGGCATCTTTAGCCACCGT-3'. Samples were run on a Lightcycler LC480 (Roche) according to the manufacturer's instructions and expression levels were compared to a standard curve. Lamc3 expression values were normalised to *eflα* expression and raw qRT-PCR data (Cp-values) are located in Supplementary data repository, [File 3](#).

Graphs and statistical analyses

Tukey box plots and bar graphs were generated using R and annotated in Adobe Illustrator. Four statistical analyses were performed in this work: Unpaired Student's t test was performed using Prism software to compare quantitative Lamc3 SBMO data to standard control embryos, and to generate p-values for qPCR of Lamc3 in Tg(*flilα:egfp*) GFP+ and GFP- cells. One-way ANOVA test for multiple comparisons were performed using Prism software to generate p-values between control, uninjected, Lamc3 SBMO, and TBMO PAC quantifications. Two-way ANOVA tests were performed using Prism software to compare the number of arterial and venous intersegmental vessels between control and Lamc3 SBMO embryos. Fisher's exact Two-tailed tests (2x2 contingency table) were performed using GraphPad software to compare the number of CRISPR/Cas9 F0 embryos with normal PAC development or PAC defects to control embryos. All raw quantified data can be found in Supplementary data repository, [File 4–File 8](#).

Zebrafish strains and maintenance

Zebrafish (*Danio rerio*) adults were maintained and bred under standard conditions (Nusslein-Volhard & Dahm, 2002). Embryos and larvae were maintained in E3 medium at 28.5°C and staged according to Kimmel *et al.*, 1995. Wild type Lon AB lines were provided by the Francis Crick Institute aquatics facility (London, UK). The transgenic line Tg(*flilα:egfp*, *gata1:dsRed*)¹ “Tg(*flilα:egfp*)” was a gift from Dr Tim Chico (MRC Centre for Developmental and Biomedical Genetics, University of Sheffield) (Lawson & Weinstein, 2002). The Tg(*flt1:yfp*)^{hu46247g} “Tg(*flt1:yfp*)” and Tg(*kdr1:Hsa.HRAS-mCherry*)⁸⁹⁶ “Tg(*kdr1:mCherry*)” lines were gifts from Dr Roger Patient (Radcliffe Department of Medicine, University of Oxford, UK) (Chi *et al.*, 2008; Hogan *et al.*, 2009). The Tg(*prox1aBAC:KalTA4-4xUAS-E1b:uncTagRFP*)^{nim5} “Tg(*prox1a:rfp*)” line was a gift from Dr Elke Ober (The Danish Stem Cell Center, University of Copenhagen, Denmark) (Dunworth *et al.*, 2014). The Tg(*gfap:gfp*)^{mi2001} “Tg(*gfap:gfp*)” transgenic line was a gift from Dr David Wilkinson (Francis Crick Institute, London, UK) (Bernardos & Raymond, 2006).

Probe synthesis and *in situ* hybridisation

Antisense DIG-labelled probes for Lamc3 mRNA were synthesised using amplified cDNA product using the following primers, with T7 promoter sequence underlined and SP6 sequence shown in italics: Lamc3 ISH Fw: 5'-TAATACGACTCACTATAGGGA-GAGGATTCCTCTGCACTTCACTCTCT-3'; Lamc3 ISH Rv: 5'-ATTAGGTGACACTATAGAAGNGTTGGCAGAATGACGAGTCGCTCGTGC-3'. DIG-labelled mRNA was synthesised using 2 µg of PCR product, purified using columns according

to manufacturer's instructions (28106, Qiagen), and SP6 RNA polymerase (11487671001, Roche) in 1× transcription buffer and DIG RNA Labeling Mix (11277073910, Roche). The zebrafish *netrin-1a* (*ntn1a*) plasmid (IRBOP991E0176D, Source Bioscience) was digested with EcoRV (R0195, NEB) according to the manufacturer's instructions. DIG-labelled mRNA was synthesised using 1 µg of linearised plasmid DNA and T7 RNA polymerase (10881775001, Roche) in 1× transcription buffer and DIG RNA Labeling Mix (11277073910, Roche). Probes were purified using Illustra Microspin G-50 columns (27-5330-01, GE Healthcare) according to the manufacturer's instructions. *In situ* hybridisation for *lamc3* and *ntn1a* were performed as described previously (Thisse & Thisse, 2008). After fixation, *in situ* hybridisation expression patterns were imaged on a Leica M165FC fluorescent microscope using Leica Application Suite 3.4.1 software. Images were cropped and brightness was adjusted using Adobe Photoshop.

Immunostaining, antibodies, and imaging

For immunostaining, all steps were performed at room temperature unless otherwise stated. Control and knockdown zebrafish embryos were fixed in 4% paraformaldehyde for 1 hour before being washed 3× in phosphate buffered saline pH7.4 (PBS) for 5 minutes each. Embryos were digested in 10 µg/ml proteinase K (AM2546, Ambion) in blocking solution (0.3% bovine serum albumin, 10% foetal calf serum, 0.2% Triton-X in PBS) for 30 minutes and refixed in 4% paraformaldehyde for 30 minutes. Next, embryos were washed 3× in PBS 0.1% Tween-20 (PBST) for 5 minutes each. Embryos were then incubated in blocking solution for 1 hour before being incubated in blocking solution with primary antibody overnight at 4°C. The next day embryos were washed 3× in PBS with 0.2% Triton-X for 10 minutes each before being incubated in blocking solution containing secondary antibody for at least 1 hour. Embryos were then washed 3× in PBS with 0.1% Triton-X for 1 hour each before a single 10 minute wash in PBST. For imaging, embryos were transferred to 75% glycerol overnight and mounted for imaging on glass cover slides. For transverse sections, embryos were cut by hand using a clean scalpel at the level of the yolk extension and mounted on glass slides with coverslips.

The following primary antibodies were used at a concentration of 1:200: rabbit anti-human LAMC3 C-terminal polyclonal primary antibody (SAB4500081, Sigma-Aldrich); rabbit anti-human NETRIN-1 (H104) polyclonal primary antibody (sc-293197, Santa Cruz Biotechnology); and mouse anti-chicken MNR/HB9/MNX1 monoclonal primary antibody (81.5C10, Developmental Studies Hybridoma Bank). Each of these antibodies was visualised using Alexa Fluor 488-conjugated goat anti-rabbit secondary (A11034, Invitrogen, Molecular Probes) used at 1:1000. The mouse anti-*Drosophila* engrailed monoclonal primary antibody (4D9, Developmental Studies Hybridoma Bank) was used at a concentration of 1:4, followed by rabbit anti-mouse HRP secondary (61-6520, Thermo Fisher Scientific) at 1:100 and Cyanine 5 tyramide reaction (SAT705A001EA, Perkin Elmer) according to the manufacturer's instructions. In all cases, samples containing no primary antibody were used as negative controls. Whole embryos or sections were imaged on a Zeiss LSM710 confocal microscope using ZEN software. Z-stacks were compiled using FIJI (Fiji Is Just Image-J) software using a Max Intensity projection.

Image manipulation

Where necessary for clarity, contrast was increased using Adobe Photoshop “Brightness/contrast” or “Curves” tools. All images were positioned to have anterior to the left and posterior to the right. Examples of such manipulated images compared to original images are shown in [Supplementary Figure 1](#).

Morpholino oligonucleotide (MO) and mRNA injection

One-cell stage embryos were injected with 1 nl solution containing up to 10 ng of antisense morpholino oligonucleotides, from Gene Tools (Philomath, OR, USA). Morpholino sequences and concentrations are shown in [Table 1](#).

For overexpression of mouse *Lamc3* mRNA, the *mLamc3* vector (IRAVp968C12150D, Source Bioscience) was linearised with NotI (R0189, NEB) according to manufacturer’s recommendations. Column purified plasmid was used as a template for *in vitro* mRNA synthesis using mMESSAGE mMACHINE SP6 transcription kit (AM1340, Ambion) according to manufacturer’s instructions. The resulting mRNA was then lithium chloride precipitated, dissolved in RNase-free water and stored in aliquots at -80°C. Either 1 nl of 200 ng/μl or 400 ng/μl of *mLamc3* mRNA was injected into single embryos at the one-cell stage.

Confocal imaging and image processing

Live embryos were transferred to a glass cover slip bottomed dish in embryo medium and 2.1 ml of stock tricaine solution (MS222, 4 mg/ml) was added per 50 ml of embryo medium. Anaesthetised animals were imaged on the Zeiss LSM710 confocal microscope using ZEN software. All images of the trunk were taken at the level of the horizontal myoseptum. 8–12 Z-stacks for images of the whole trunk, or 4–6 Z-stacks for images from the embryo midline to the distal surface of the embryo were collected at approximately 8 μm intervals. Z-stacks were compiled using

Fiji (Fiji Is Just Image-J) software using “Max Intensity” projections.

CRISPR/Cas9 mutagenesis and imaging

Custom CRISPR short guide RNAs (sgRNAs) targeting exon 1 of *lamc3* were designed using CRISPR Design tool (crispr.mit.edu) to span an endonuclease target site and constructed using the oligonucleotides shown in [Table 2](#) generated by ZiFiT Targeter ([Sander et al., 2010](#)). 100 μM oligonucleotides were phosphorylated and annealed using T4 Polynucleotide kinase (M0201, NEB) in ligation buffer for 30 mins at 37°C, 95°C for 5 minutes, and cooled to room temperature over two hours. The DR274 plasmid (a gift from Keith Young – Addgene plasmid #42250) was linearised by BsaI (R0535, NEB) digestion according to manufacturer’s instructions and gel purified (28706, Qiagen). Phosphorylated, annealed oligonucleotides (diluted 1:200) were ligated into the DR274 plasmid using the Quick ligation kit (M2200, NEB) and Plasmid Safe treatment (E3105K, Cambridge Bioscience). Template DNA was amplified from DR274 using Phusion High Fidelity polymerase (M0530, NEB) using the following primers: Fw: 5'-GCTCGATCCGCTCGCACC -3'; Rv: 5'-AAAAGCACCGACTCGGTGCC-3'; according to the manufacturer’s instructions. PCR products were gel purified (28706, Qiagen) and sgRNAs were transcribed using T7 MegaShortScript transcription kits (AM1354, Ambion) and purified using RNeasy Mini kits (74104, Qiagen) according to the manufacturers’ instructions. sgRNA quality was checked by running on a 2% agarose gel, quantified using a Nanodrop spectrophotometer and stored in aliquots at -80°C. Cas9 mRNA was synthesised from the MLM3613 plasmid (a gift from Keith Young – Addgene #42251) as described previously ([Hwang et al., 2013](#)). Cas9 mRNA was purified by lithium chloride precipitation and stored in aliquots at -80°C. Two clutches of Tg(*flila:egfp*) zebrafish embryos were injected at the one-cell stage with 1 nl of solution containing ~12–15 ng/μl of each *Lamc3*

Table 1. Sequences for morpholino oligonucleotides.

Morpholino	Approximate concentration per embryo	Sequence (5'-3')
Std control	10 ng	CCTCTTACCTCAGTTACAATTATA
p53	2.5 ng	GCGCCATTGCTTTGCAAGAATTG
<i>Lamc3 e1i1</i>	5 ng	AGCCCAGTAGGGAGTCTTACCAAGA
<i>Lamc3</i> translation-blocking	5 ng	AGTGAAGTGCAGAGGAATCCATCCT

Table 2. Sequences for sgRNA oligonucleotides.

Oligonucleotide for sgRNA synthesis	Sequence (5'-3')
<i>Lamc3</i> sgRNA1 Oligo 1	TAGGACTACTGCATGCAGAC
<i>Lamc3</i> sgRNA1 Oligo 2	AAACGTCTGCATGCAGTAGT
<i>Lamc3</i> sgRNA2 Oligo 1	TAGGCGATTAGCTCAGAGTCGA
<i>Lamc3</i> sgRNA2 Oligo 2	AAACTCGACTCTGAGCTAAATCG

sgRNA and ~300 ng/μl of Cas9 mRNA. In addition, sgRNA alone or Cas9 mRNA alone were injected as negative controls. Embryos were imaged at 2 dpf on a Leica M165FC fluorescent microscope using Leica Application Suite 3.4.1 software. Embryos that lacked a parachordal chain in more than 5 segments of the trunk at the level of the yolk extension were recorded as having parachordal chain defects.

Genotyping

To extract genomic DNA, single 48 hpf embryos or tail fin clips of individual adult fish were incubated for up to 3 hours at 55°C in 20–50 μl of genomic DNA extraction buffer (50 mM Tris-HCl pH 8.5, 1 mM EDTA, 0.5% Tween-20) with fresh 0.08 μg/ml Proteinase K (AM256, Ambion) added before use. Samples were then heated to 95°C for 10 minutes to inactivate proteinase K and debris was spun down using micro centrifugation. The sgRNA target site was amplified from extracted genomic DNA using the following primers: Fw: 5'-TTCTGCTTTTGGCAGCGTC-3'; Rv: 5'-GCAATACCAGCACTGCTCTAC-3'. Mutation of the target site was identified by digestion with SphI-HF (R3182, NEB) or TaqαI (R0149, NEB) for sgRNA1 and sgRNA2 respectively, overnight at 37°C according to the manufacturer's instructions. After digestion, samples were run on a 2% agarose gel for 30 minutes at 120V and compared to a 100 bp ladder (15628-050, Life Technologies). For SphI digests, complete digestion of wild type product produces three bands of 84, 164 and 263 bp. Some animals were later identified to contain a single nucleotide polymorphism (SNP) in one of the SphI sites. Complete digestion of wild type genomic DNA in such animals produces two bands of 164 and 346 bp. Digestion of mutant product yields bands of 83 and 427 bp, or 510 bp if the SNP is present. For TaqαI digests, complete digestion of wild type PCR product produces two bands of 205 and 305 bp. Digestion of mutant products yields a single band of 510 bp. For presentation, agarose gel images were inverted and cropped but were not otherwise manipulated.

Protein extraction and western blot

48 hpf zebrafish embryos were dechorionated in batches of around 100 and transferred to ice cold Calcium-free Ringer's solution. Embryos were rinsed 3× in Ringer's solution. Samples were then transferred to ice cold Ringer's solution containing 1mM EDTA and 0.3 mM phenylmethylsulfonyl fluoride (PMSF). Embryos were de-yolked by pipetting using a 200 μl pipette tip. De-yolked embryos were then rinsed twice in Ringer's solution with EDTA and PMSF, and snap frozen on dry ice. Frozen embryos were thawed and homogenised in 100 μl of protein extraction buffer (1% IGEPAL, 150 mM NaCl, 20 mM Tris pH 7.5, 2 mM EDTA, 50 mM NaF, 1mM sodium pyrophosphate) with 1× cOmplete

Mini Protease Inhibitor Cocktail (1183615300, Roche) overnight at 4°C with rotation. Samples were pelleted and 150 μl of 1× Laemmli sample buffer was added (161-0737, BioRad). Pellets were homogenised in sample buffer using a microfuge pestle in a round-bottom 1.5 ml tube. Before loading, samples were boiled at 99°C for 5 minutes.

20 μl of protein extract was loaded into a NuSEP 4–20% glycine pre-cast gel with Spectra multicolour broad range protein ladder (SM1849, Thermo Scientific) and run in SDS running buffer for 1 hour at 100V. Proteins were transferred to methanol-activated Immobilon-P PVDF membranes (Millipore) in Tris-Glycine transfer buffer. Transfer was performed for approximately 1 hour at 400 amps with ice cooling. Membranes were blocked in 5% milk powder in PBST (phosphate buffered saline pH7.4, 0.1% Tween-20) for 1 hour at room temperature. Membranes were incubated with rabbit anti-human NETRIN-1 (H104) polyclonal antibody (sc-293197, Santa Cruz Biotechnology) was in 5% milk powder blocking solution. For data presented in this work, the antibody was used at a concentration of 1:100, although bands of identical molecular weights can also be detected up to a concentration of 1:1000. Membranes were rinsed with 5 washes in PBST before being incubated with goat anti-rabbit HRP-conjugated antibody (31460, Thermo Scientific) 1:2000 in 5% milk powder blocking solution for 2 hours at room temperature. Membranes were rinsed 3× in PBST at room temperature. Protein bands were visualised using chemifluorescence, SuperSignal West Dura Extended Duration Substrate (34075, Thermo Scientific) according to manufacturer's instructions and exposed using the ChemiDoc gel imaging system (BioRad). An image of the gel prior to cropping and brightness/contrast manipulation can be found in the Supplementary data repository, [File 9](#). Molecular weights were compared to the protein ladder and putatively identified according to predicted molecular weights ([Table 3](#)).

Results

Lamc3 is expressed by endothelial cells

Amino acid sequences of human, mouse, and zebrafish laminin γ1, γ2, and γ3 chains were aligned using MUSCLE ([Figure 1A](#)). Zebrafish laminin γ3 is a large protein (1643 amino acids) with several annotated domains including a laminin-binding domain at the N-terminus, 11 epidermal growth factor-like (EGF-like) binding domains, a laminin IV (L4) domain (the function of which is unknown), and a C-terminal coiled-coil domain ([Domogatskaya et al., 2012](#)). Phylogenetic analysis of human, mouse, and zebrafish LAMC1, LAMC2, and LAMC3 proteins shows that LAMC3 is most closely related to LAMC1 ([Figure 1B](#)). LAMC3 is unable to bind integrins because it

Table 3. Predicted molecular weights of zebrafish Netrin-1 proteins using ExPASy Compute pI/MW tool. aa, amino acids; kDa, kilo Daltons; MW, molecular weight.

ENSEMBL Transcript ID	Name	Uniprot code	Size (aa)	Predicted MW (kDa)
ENSART00000157527.1	Nertrin-1a	O42140_DANRE	603	65307.06
ENSART00000171384.1	Nertrin-1a	A0A0R4IN40_DANRE	446	48191.08
ENSART00000039482.4	Nertrin-1b	F1QUK5_DANRE	602	65338.19




Figure 1. *Lamc3* expression during zebrafish development. (A) MUSCLE-aligned protein "fingerprints" of zebrafish (*Danio rerio*, Dre), human (*Homo sapiens*, Hsa), and mouse (*Mus musculus*, Mmu) LAMC1, LAMC2, and LAMC3 amino acid sequences with RasMol colouring. (B) Unrooted RaxML phylogenetic tree (JTT+Gamma model) of *Nematostella vectensis* (purple, Nve) Lamc1-like and human (red, Hsa), mouse (orange, Mmu), and zebrafish (blue, Dre) LAMC1, LAMC2, and LAMC3 proteins. Branch labels denote ML bootstrap values (100). (C) Aligned human, mouse, and zebrafish amino acid sequence of the laminin $\gamma 1$ and $\gamma 3$ C-terminal tails show that the loss of the essential glutamic acid residue in $\gamma 3$ is conserved across vertebrates. (D) qRT-PCR shows *lamc3* is not significantly enriched in *gfp+* endothelial cells ($1.85\text{E-}05 \pm 5.49\text{E-}06$, $n=3$) compared to GFP- cells ($6.28\text{E-}06 \pm 1.48\text{E-}06$, $n=4$) sorted from 26 hpf Tg(*flil1a:egfp*) embryos. Expression is relative to *ef1a* expression and normalised to GFP+ population (100%). All values are mean $\pm$ s.e.m. P-value determined by Unpaired Two-tailed Student T-test. (E–F) Whole-mount *in situ* hybridisation showing *lamc3* expression in the whole embryo and enlarged lateral view of the trunk as indicated. (E) At 26 hpf *lamc3* is expressed in the head vasculature and in major trunk vasculature ($n=10$). (F) At 48 hpf *lamc3* is also expressed in myotomes at the level of the horizontal myoseptum ($n=15$). (G–H) Immunostaining using an anti-LAMC3 C-terminal antibody. (H) At 26 hpf Lamc3 protein is localised in the dorsal region of the trunk and at the level of the HMS (arrowhead, $n=10$). (I) By 48 hpf protein is also detected ventrally in the region of the dorsal aorta and posterior cardinal vein ($n=5$). A, anterior; D, dorsal; dpf, days post fertilisation; hpf, hours post fertilisation; n, number of cDNA samples. Scale bars: 100 μm .

lacks an essential glutamic acid residue in the C-terminal tail (Ido *et al.*, 2008). Amino acid alignments showed that this is conserved between vertebrates (Figure 1C).

High-throughput sequencing of sorted 26–28 hpf Tg(*flil1a:egfp*) zebrafish embryos had suggested that *lamc3* is enriched 4-fold in *flil1a:gfp* expressing (GFP+) endothelial cells (Cannon *et al.*, 2013). To verify this observation we performed qRT-PCR on cDNA synthesised from FACS sorted 26 hpf Tg(*flil1a:egfp*) embryos. Our results revealed only a 3-fold enrichment that was not statistically significant ($p=0.0562$, Unpaired Student's t-test) in GFP+ cells compared with the rest of the embryo. This observation confirms that *lamc3* is expressed by GFP+ cells, but suggests that other cells also express the gene (Figure 1D). *Flil1a* is also expressed in the pharyngeal arch and neural crest (Lawson & Weinstein, 2002). Therefore, to determine whether the Lamc3 detected in GFP+ cells derives from endothelial cells, we investigated the spatial expression of *lamc3* by whole-mount

in situ hybridisation. In 26 hpf embryos, *lamc3* is expressed in the head and vasculature ($n=10$) (Figure 1E). In addition, expression is seen in the fin bud and myotome at the level of the horizontal myoseptum at 48 hpf ($n=15$) (Figure 1F). These data are consistent with published *in situ* hybridisation patterns and suggest that *lamc3* is expressed in both vascular endothelium and non-endothelial cells, including the middle cerebral vein, dorsal neuronal plate, and gut (Sztal *et al.*, 2011).

Laminins are secreted proteins, so we used whole-mount immunostaining to ask whether laminin $\gamma 3$ protein ($\gamma 3$) is found adjacent to regions of gene expression (Figure 1G–H). At 26 hpf, low levels of $\gamma 3$ were detected in the dorsal floor plate of the neural tube and the horizontal myoseptum, but no protein was observed in the trunk vasculature ($n=10$). At 48 hpf ($n=5$) $\gamma 3$ protein overlaps with *lamc3* expression: protein is located at the horizontal myoseptum, the dorsal plate of the neural tube, and axial vessels in the trunk (Figure 1H'). To show that this was specific to $\gamma 3$, we

overexpressed mouse *Lamc3* mRNA in zebrafish embryos and detected a dose-dependent increase in labelling in these regions at 24 hpf (Figure S2 A–C). We believe that overexpressed protein accumulates in regions of endogenous expression because suitable laminin alpha and beta chains need to be co-expressed to form a heterotrimeric complex.

Lamc3 knockdown embryos have depleted $\gamma 3$ protein

To validate *Lamc3* knockdown, embryos injected with standard control morpholino or *Lamc3* SBMO were immunostained using the human anti-LAMC3 C-terminal antibody. Control embryos (n=11/12) showed $\gamma 3$ protein in the dorsal plate of the neural tube, horizontal myoseptum and ventral vasculature as seen previously (Figure 2A). In *Lamc3* knockdown embryos (n=10) we observed a reduction in $\gamma 3$ protein in the vasculature and horizontal myoseptum although it is possible that some protein persists in the dorsal neural plate (Figure 2B).

Lamc3 is required for parachordal chain (PAC) formation

Lamc3 is expressed in *flila*⁺ endothelial cells, so we asked whether $\gamma 3$ is required for zebrafish vascular development. To this end, we injected translation blocking (TBMO) and splice-blocking morpholino oligonucleotides (SBMO) targeting *Lamc3* mRNA into Tg(*flila*:egfp) embryos and observed the developing vasculature over the following 3 days. A minority of MO injected embryos exhibited phenotypes associated with MO toxicity, including cell death and oedema in the head (Figure S3 A,B) (Eisen & Smith, 2008). For this reason, in the experiments that follow we co-injected MOs with p53 MO to control for off-target effects.

Our results show that in uninjected (n=19) or standard control morpholino injected embryos (n=16) the parachordal chain (PAC, white arrowhead) develops between the intersegmental vessels at the level of the horizontal myoseptum (Figure 2C,E). In embryos injected with *Lamc3* SBMO (n=34) and TBMO (n=30) the PAC fails to develop (Figure 2D,F). To account for any developmental delay causing the PAC defect, control or *Lamc3* knockdown embryos were allowed to develop until 72 hpf. At 72 hpf *Lamc3* SBMO injected embryos (n=38) recovered development of the dorsal longitudinal anastomotic vessel (DLAV) but the PAC remained absent (Figure 2G,H). In *Lamc3* TBMO embryos (n=16) the common cardinal vein had enclosed the perimeter of the yolk, but the embryos continued to lack a PAC (Figure S3C). These data suggest that the defects in PAC development are not a result of general developmental delay. Quantification of the number of PACs per intersegmental vessel determined that *Lamc3* knockdown embryos had significantly fewer ($p < 0.0001$, One-way ANOVA test for multiple comparisons) PACs compared to controls at both time points (Figure 2I). This phenotype persisted longer using the *Lamc3* SBMO, and this MO was therefore used in all subsequent experiments.

Loss of the PAC in embryos lacking $\gamma 3$ could result from failure of the venous intersegmental vessels to sprout dorsally from the posterior cardinal vein (Hogan *et al.*, 2009). To determine if *Lamc3* knockdown prevents venous sprouting, Tg(*flt1*:yfp;*kdrl*:mCherry) embryos were injected with *Lamc3* SBMO and venous


intersegmental vessels were identified by their lack of *flt1* expression, which is specific to arterial endothelium (Swift & Weinstein, 2009). At 72 hpf, both standard control (n=16) embryos have vessels that lack *flt1* expression (white outline), which form the PAC and venous intersegmental vessels (Figure 2J). Laminin $\gamma 3$ -depleted embryos (n=18) also showed intersegmental vessels of venous origin (white outline) that did not express *flt1*:yfp (Figure 2K). Numbers of arterial ($p = 0.9718$) and venous ($p = 0.5326$) intersegmental vessels were counted and were not significantly different (Two-way ANOVA test) between control and *Lamc3* knockdown embryos (Figure 2L). This suggests that *Lamc3* is not required for sprouting from the cardinal vein.

Lamc3 knockdown embryos do not develop a thoracic duct

The parachordal chain is the source of lymphatic endothelial cells that form the thoracic duct (Okuda *et al.*, 2012). Therefore, we asked whether thoracic duct development is affected by *Lamc3* knockdown. Tg(*flila*:egfp;*prox1a*:rfp) embryos were injected with *Lamc3* SBMO (n=12) or standard control MO (n=12) and were observed at 5 dpf for the presence or absence of the thoracic duct, identified by expression of *prox1a*. Despite increasing in size, $\gamma 3$ -deficient embryos were severely morphologically abnormal compared with controls (Figure 2M,N). In control embryos (n=12) the thoracic duct (white outline, white arrowhead) is clearly visible between the dorsal aorta and posterior cardinal vein (Figure 2O). We observed no *prox1a*-expressing thoracic duct cells in *Lamc3* SBMO injected embryos (Figure 2P). To quantify this observation, the numbers of hemisegments with a thoracic duct were counted and $\gamma 3$ -deficient embryos had a significant ($p < 0.0001$, Unpaired Student's t test) reduction compared to controls (Figure 2Q). It was unclear whether the lack of thoracic duct in *Lamc3* SBMO embryos is a result of developmental delay, caused by an earlier developmental defect or as a direct result of $\gamma 3$ -deficiency.

CRISPR/Cas9 genetically modified F0 embryos recapitulate the MO knockdown phenotype

Recent work has suggested that antisense morpholinos may cause misleading results through off-target effects, and may not always represent a true loss-of-function phenotype (Kok *et al.*, 2015). To address this concern, we used the CRISPR/Cas9 system to genetically alter the *lamc3* gene in F0 embryos. Previous work has shown that this approach can yield biallelic mutant embryos that recapitulate morpholino knockdown phenotypes (Jao *et al.*, 2013). Two sgRNAs targeting the first exon of *lamc3* were designed (Figure 3A). Each sgRNA was injected into 1-cell Tg(*flila*:egfp) embryos together with Cas9 mRNA, and Cas9 mRNA alone was also injected as a negative control. At 2 dpf embryos were assessed for formation of the PAC. Of embryos injected with Cas9 mRNA alone (n=70), only 1 had developmental defects (Figure 3B,E). Of embryos injected with sgRNA1 and Cas9 mRNA (n=120), the majority of embryos looked morphologically normal although a small number (<5%) showed signs of toxicity such as curvature of the body axis and intersegmental vessel defects. 44 had five or more absent PACs, significantly more ($p < 0.0001$, Fisher's exact Two-tailed test) than those injected with Cas9 mRNA alone (Figure 3C,E). In contrast, the majority of embryos injected with sgRNA2 and Cas9 mRNA (n=112/114) had normal PAC development (Figure 3D,E).






Figure 3. CRISPR/Cas9 mutagenesis of *lamc3* causes defects in parachordal chain (PAC) development. (A) Design of sgRNAs targeted to exon1 of the *lamc3* gene. Each sgRNA targets a restriction endonuclease site used for genotyping and is upstream of a protospacer adjustment motif (PAM). (B–D) Cas9/sgRNA injected embryos (as labelled) at 50 hpf. (B–D) Brightfield images show no developmental defects or developmental delay. (B'–D') Whole embryo images of Tg(*fli1a:egfp*) fluorescence area indicated by white dotted line is enlarged in (B''–D'') the PAC in each hemisegment is indicated with a red asterisk. (E) Quantification of Tg(*fli1a:egfp*) embryos at 50 hpf with PAC defects. P-values determined by Fisher's exact Two-tailed test compared to Cas9 alone controls. (F–I) 2% agarose genotyping gels with 100 bp ladder. (F) Schematic diagram of the region amplified by PCR contains two SphI sites (orange), which would digest into three fragments of 83, 164 and 263 bp in length. Predicted mutation of one of these sites will produce two bands of 83 and 427 bp in length. A natural variant contains a SNP in the second SphI site, complete digestion of this variant would produce two bands of 164 and 346 bp in length. Mutation of the target SphI site would prevent digestion of the fragment. Digestion of the amplicon with TaqI (blue) in wild type embryos will yield two fragments of 204 and 306 bp in size. (G) Restriction endonuclease digest of target region shows undigested mutant products (black asterisk) at a size of 427/510 bp in sgRNA1-injected embryos. (H) Fewer undigested mutant products (510 bp) were observed in sgRNA2-injected embryos. (I) Brightfield images sgRNA1/Cas9 injected embryo at 5 dpf shows severe oedema. (J) Genotyping of 3-month adult fish. A, anterior; b/bp, base pairs; d, days post fertilisation; D, dorsal; kb, kilobases; mpf, months post fertilisation; n, number of embryos; PAC, parachordal chain; PAM, protospacer adjustment motif; SBMO, splice-blocking morpholino; sgRNA, short guide RNA; U, undigested control;.

Random restriction enzyme genotyping of injected single embryos showed that sgRNA1 was more effective than sgRNA2 at inducing mutations (Figure 3F–H). We also observed biallelic mutations from injection of sgRNA1 and Cas9 mRNA (Figure 3G). Considerably fewer mutant cells and no biallelic mutations were detected in embryos injected with sgRNA2, so these embryos might serve as a negative control for sgRNA-induced off target effects (Figure 3H). Indeed, most embryos injected with sgRNA2 developed normally (Figure 3D–E). To show that PAC defects were not a nonspecific result caused by introduction of short oligonucleotides into the cell, embryos were injected with sgRNA1 alone or with Cas9 mRNA. A few embryos (n=3/51) had developmental defects when Cas9 mRNA was absent (Figure S4A), whereas significantly more (p=0.0056, Fisher's exact two-tailed test) defects were observed in embryos with both Cas9 mRNA and sgRNA1 (Figure S4B). These observations, together with the morpholino knockdown data, lead us to conclude that PAC development is affected by γ 3-deficiency.

We attempted to generate a stable *lamc3* mutant line by injecting Tg(*fli1a:egfp*) embryos with Cas9 mRNA and sgRNA1. However, by 5 dpf almost half (n=31/72) of the injected embryos presented severe oedema, with swelling around the eyes (red lines), heart, gut and yolk (Figure 3I). In addition, we observed partial reductions in eye size (white arrowhead) and defects in otic vesicle formation (black outline). Larvae with oedema were reproduced in subsequent injections and not kept past 5 dpf. Of the embryos that survived beyond 5 dpf, only 12 reached breeding age. Genotyping of these adults indicated little or no mutagenesis in these animals (Figure 3J) and no heterozygous *lamc3* mutants were recovered from subsequent crosses. Because we have been unable to create a *lamc3* mutant line using CRISPR/Cas9, subsequent experiments make use of antisense morpholino oligonucleotides.

Notochord development is unaffected in *Lamc3* knockdown embryos

Mutations in other laminins cause notochord defects that prevent proper angiogenesis (Odenthal *et al.*, 1996; Parsons *et al.*, 2002; Pollard *et al.*, 2006). Sonic hedgehog derived from the notochord is crucial for the specification of muscle pioneers at the horizontal myoseptum, which develop into slow-twitch muscle (Blagden *et al.*, 1997). To see if notochord development was perturbed in *Lamc3* knockdown embryos we asked if muscle pioneers were induced at 36 hpf. Immunofluorescence using the 4D9 anti-Engrailed antibody in both control (n=5) and knockdown (n=6) embryos showed that muscle pioneer cells were indeed specified at the horizontal myoseptum (Figure 4A–B). This distinguishes the role of γ 3 in angiogenesis from that of other laminins that are required for notochord development (Dolez *et al.*, 2011). We then asked whether slow-twitch muscle also developed normally in *Lamc3* morphants using the Tg(*prox1a:rfp*) line. In control embryos (n=6) *prox1a:rfp* was expressed in the neural tube, caudal motoneurons and slow-twitch muscle (Figure 4C). Transverse sections showed slow-twitch muscle flanking the neural tube along the length of the embryo (Figure 4C'). To our surprise, ectopic *prox1a:rfp* was expressed in unknown cells at the horizontal myoseptum (black arrowheads) in *Lamc3* morphants (Figure 4D'). However *prox1a:rfp* was also expressed in the somites, suggesting that slow-twitch muscle does differentiate, although it has not

as migrated as far to the periphery of the embryo as in controls (Figure 4D').

Netrin-1 is affected by *Lamc3* knockdown

Muscle pioneers express *netrin-1a* at the horizontal myoseptum and knockdown of the zebrafish Netrin-1a and its cognate receptors: *unc5b* and *cd146* prevents formation of the PAC, phenocopying *Lamc3* knockdown (Navankasattusas *et al.*, 2008; Park *et al.*, 2004). Furthermore, Netrin-1 provides guidance for the axon migration of motoneurons, which are required for PAC development (Hale *et al.*, 2011; Lauderdale *et al.*, 1997; Lim *et al.*, 2011). To ask whether the expression of *netrin-1a* by muscle pioneers is disturbed, we performed *in situ* hybridisation on 36 hpf control and *Lamc3* knockdown embryos. We found that expression of *netrin-1a* by muscle pioneer cells was not altered in *Lamc3* morphants (n=11) compared with control embryos (n=12). To our surprise however, the expression domain of *netrin-1a* appeared to be broader in γ 3-deficient embryos, with increased expression in the neural tube (Figure 4E,F).

To visualise Netrin-1 protein, immunofluorescence was performed on 50 hpf control (n=10/14) and *Lamc3* SBMO (n=8) injected Tg(*kdr1:mCherry*) embryos using a human anti-NETRIN-1 polyclonal antibody. This antibody was chosen because its epitope is highly conserved between human and zebrafish Netrin-1a and Netrin-1b proteins. In control embryos, we observed Netrin-1 protein in the neural tube and in the middle of somites (white outline) in the trunk (Figure 4G). Netrin-1 protein was reduced in all *Lamc3* knockdown embryos at the level of the horizontal myoseptum compared with controls (Figure 4H). However, transverse sections showed that Netrin-1 was widely dispersed in *Lamc3* knockdown embryos and that Netrin-1 protein was located throughout the majority of the trunk (Figure 4H'). We validated the anti-NETRIN-1 antibody by Western blot using protein extracts from whole 48 hpf zebrafish embryos either uninjected or injected with *Lamc3* SBMO. Results showed two bands corresponding to the predicted molecular weights of zebrafish Netrin-1 splice variants (Figure 4I).

Rostral primary motoneurons are affected by *Lamc3* knockdown

The development of the PAC depends on the correct migration of rostral primary motoneurons, which extend axons along the horizontal myoseptum in response to Netrin-1a signalling (Hale *et al.*, 2011; Lim *et al.*, 2011). *Netrin-1a* expression is perturbed in *Lamc3* knockdown embryos and *LAMC3* has an important role in mammalian neuronal development, so we investigated motoneuron development in γ 3-deficient embryos (Gnanaguru *et al.*, 2013; Li *et al.*, 2012; Tanabe *et al.*, 1998). We used an anti-HB9 (MNX1) antibody and a transgenic Tg(*gfap:gfp*) zebrafish line to ask whether primary motoneurons are affected by *Lamc3* knockdown at 48 hpf.

In 48 hpf control embryos (n=5) HB9 positive cells are elongated along the anterior-posterior axis and are concentrated at the dorsal neural tube and horizontal myoseptum (Figure 4J). The motoneurons in *Lamc3* knockdown embryos are found in similar regions, although they have a rounded morphology (Figure 4K). The total number of HB9 positive motoneurons in *Lamc3* knockdown embryos (73±12) did not differ significantly from




Figure 4. Lamc3 knockdown affects rostral primary motoneuron (RoP) migration. (A–B) Lateral view of 36 hpf embryos stained for muscle pioneers (MPs, underlined) using 4D9 anti-engrailed show MPs present in both control (A, n=5) and knockdown embryos (B, n=6). (C–D) 48 hpf Tg(*prox1a:rfp*) embryos injected with standard control (C, n=6) or Lamc3 SBMO (D, n=6) have increased *prox1a* expression in the trunk. Transverse sections in E' and D' show additional *prox1a* expressing cells at the horizontal myoseptum in Lamc3 SBMO embryos. (E–F) Whole-mount *in situ* hybridisation for *netrin-1a* expression at 36 hpf. *Netrin-1a* is expressed in MPs and neural tube (NT) in both control (E, n=12) and knockdown embryos (F, n=11). Highlighted regions are enlarged in E' and F' and indicate an increased expression domain in the NT of knockdown embryos. (G–H) Lateral view of the trunk of 50 hpf Tg(*kdr:l:mCherry*) (magenta) embryos stained for Netrin-1 (anti-NETRIN-1, green). Loss of Netrin-1 at the horizontal myoseptum (HMS) in knockdown embryos (H, n=8) compared to controls (G, n=10/14). Transverse sections of the embryo trunk in G' and H' shows Netrin-1 protein is restricted to the HMS and periphery in controls, but is widely distributed through the embryo in Lamc3 knockdown embryos. (I) Western blot of whole zebrafish embryo extracts using the human anti-NETRIN-1 polyclonal antibody shows two bands of molecular weights between 50–70 kDa. (J–L) HB9 (anti-MNR2) immunostaining of motoneurons. Knockdown embryos (K, n=5) show change in cell morphology and organisation compared to controls (J, n=5). (L) Quantification of HB9 positive cells shows no significant difference between control and knockdown embryos, represented as a scatter plot showing mean and standard deviation. P-value determined by Student's t test. (M–O) Tg(*gfap:gfp*) embryos injected with standard control (M) or Lamc3 SBMO morpholino (N). Lamc3 knockdown (n=12) showed increased branching of caudal primary motoneurons (CaP, red outline), and a loss of RoPs (yellow outline) at the horizontal myoseptum compared to controls (n=12). (O) Quantification of RoPs at the horizontal myoseptum per CaP represented as a Tukey box plot. There was a significant ($p < 0.0001$) reduction of RoPs in Lamc3 knockdown embryos. P-value determined by Student's t test. n, number of CaPs (number of embryos). Small white arrowhead denotes the horizontal myoseptum. A, anterior; D, dorsal; CaP, caudal motoneuron; h, hours post fertilisation; M, medial; MP, muscle pioneers; NT, neural tube; RoP, rostral primary motoneurons. Scale bars: 100 μ m.

controls (72 ± 11 ; $p > 0.05$, Unpaired Student's *t* test) suggesting that *Lamc3* is not required for specification of HB9 positive motoneurons but may be required for regulating their shape or polarity (Figure 4L).

To study motoneurons in more detail, *Lamc3* was knocked down in Tg(*gfap:gfp*) embryos. In control embryos ($n=12$) the caudal motoneuron (CaP) extends axons ventrally through the somite (red outline). Rostral motoneurons (RoPs) extend axons ventrally to the level of the horizontal myoseptum and then move anteriorly (yellow outline, Figure 4M). *Lamc3* knockdown embryos ($n=12$) show that although CaPs migrate normally, they branch more frequently (Figure 4N). Furthermore, the number of RoPs at the horizontal myoseptum is significantly reduced ($p < 0.0001$, Unpaired Student's *t*-test) and additional rounded *gfap:gfp* expressing cells are found in the trunk of the embryos (Figure 4N,O). The specification of HB9 positive cells and CaPs suggests that neural tube development is not affected by *Lamc3* knockdown and that *Lamc3* is not necessary for motoneuron specification, but may be required for regulating morphology, polarity or axon migration.

Discussion

Ectopic *prox1a*-expressing cells at the horizontal myoseptum

Prox1a is expressed by a number of tissues including slow-twitch muscle, motoneurons, and thoracic duct (Dunworth *et al.*, 2014). We were unable to determine the nature of the additional *prox1a*-expressing cells seen in *Lamc3* knockdown embryos (Figure 4D), but bearing in mind their location we suggest these represent muscle pioneers. These data indicate there may be a delay in muscle pioneer differentiation into slow twitch muscle, or else indicate that several cell types at the horizontal myoseptum are affected by *Lamc3* knockdown. This requires further investigation.

Study of Netrin-1 in *Lamc3* knockdown embryos

Netrin-1a expression was up-regulated in the neural tube of *Lamc3* knockdown embryos. Although this might explain the increase of Netrin-1 protein observed in transverse sections, the way in which Netrin-1a is regulated by *Lamc3* remains unclear. Western blot analysis of zebrafish proteins indicates that the antibody used is specific to Netrin-1, and immunostaining appears to recapitulate the Netrin-1a *in situ* hybridisation expression pattern in muscle pioneer cells. However, we were unable confidently to distinguish between Netrin-1a and Netrin-1b. We suggest that further analyses using this antibody might benefit from immunofluorescence staining on Netrin-1a morphants or western blot analyses of protein extracted from Netrin-1a knockdown embryos.

Use of morpholino oligonucleotides and CRISPR/Cas9 technologies

In recent years several technical concerns have been raised suggesting that morpholino oligonucleotides cause phenotypes that are not recapitulated in genetic mutants (Kok *et al.*, 2015; Novodvorsky *et al.*, 2015). Indeed, our own group has also shown discrepancies between the phenotypes of morphants and mutants (Eve *et al.*, 2017; Place & Smith, 2017). Such variation between phenotypes might be caused by genetic compensation, maternal mRNA and protein

contributions in mutant embryos, or nonspecific off-target effects of morpholino injection (Kok *et al.*, 2015; Maurya *et al.*, 2013; Rossi *et al.*, 2015). We were keen to generate a *lamc3* mutant line with which to explore *Lamc3* function and were disappointed that our initial attempts suggested that such animals would not be viable. Although the oedema seen in *lamc3* CRISPR/Cas9 injected F0 larvae was in tissues which endogenously express *lamc3* (specifically the gut, eye, and otic vesicle) it remains possible that this is a non-specific effect rather than a phenotype of $\gamma 3$ -deficiency, because no oedema was observed in *Lamc3* SBMO embryos at 5 dpf. Although further attempts to generate a *lamc3* genetic line were not possible within the scope of this work, we would encourage attempts to generate a *lamc3* loss-of-function mutant in any further study of *Lamc3*, as suggested by the zebrafish community (Stainier *et al.*, 2017). We suggest that viability might be improved by targeting a different region of the gene or functional domain of the protein.

Because we were unable to generate a mutant line, genetic investigations were limited to F0 CRISPR/Cas9 injected embryos, which phenocopy the PAC defects seen in MO knockdown embryos. Although previous studies have used F0 CRISPR/Cas9 injections to complement morpholino knockdown data, this technology is not without limitations (Jao *et al.*, 2013; Kim *et al.*, 2017; Sharma *et al.*, 2016). First, cells in such embryos are mosaic and may carry different types of mutation, or indeed no mutation at all. While we could show that high levels of mutagenesis in sgRNA1 injected embryos correlated with the presence of the PAC phenotype we cannot be confident that all cells in the embryo carried the same mutations, and nor whether these were true loss-of-function mutations. Therefore, the interpretation of these results in whole embryos is challenging. Second, introduction of sgRNAs might cause off-target effects like those seen with morpholinos. We did not see any PAC defects using sgRNA2 that proved ineffective at inducing mutations, nor did we see significantly more defects when injecting sgRNA1 without Cas9, supporting the contention that PAC defects were not off-target effects.

Lamc3 and neuronal guidance

We observed that rostral primary motoneurons failed to migrate properly and caudal primary motoneurons had ectopic branches in *Lamc3* knockdown embryos. This suggests that laminin $\gamma 3$ is required for motoneuron axon guidance. If this is the case, the observed defects in parachordal chain development are likely to be a consequence of an earlier neuronal defect (Lim *et al.*, 2011). A role for *LAMC3* in neuronal migration has already been described in mammals. In mice, double knock out of *Lamb2* and *Lamc3* affected the migration of astrocytes and dopaminergic neurons in the developing retina, where *Lamc3* is highly expressed (Dénes *et al.*, 2007; Gnanaguru *et al.*, 2013; Li *et al.*, 2012; Pinzón-Duarte *et al.*, 2010). Although this is a different system from the zebrafish trunk, these data might suggest a conserved role for $\gamma 3$ in vertebrate neuronal guidance, warranting further exploration.

The mechanism by which *Lamc3* might regulate axon migration also remains unclear. Laminin $\gamma 3$ might repel axon growth cones directly as described previously for laminin-1 (Höpker *et al.*, 1999; Ratcliffe *et al.*, 2008). Excessive motoneuron branching is also

observed when guidance of the axon growth cones is disturbed, such as in N-cadherin or PlexinA3 knockdown embryos (Brusés, 2011; Feldner *et al.*, 2007). Furthermore, the *lamal* zebrafish mutant, *bashful*, also has axon guidance defects including branched caudal motoneurons and the absence of the rostral primary motoneuron, which might indicate laminin $\alpha 1$ and laminin $\gamma 3$ form a complex for axon guidance (Paulus & Halloran, 2006). Amino acid sequence analysis showed that zebrafish $\gamma 3$ lacks a glutamic acid residue required for binding integrins (Ido *et al.*, 2008). This suggests that $\gamma 3$ might not be able to interact with cells directly, although $\gamma 3$ may still bind through an alternative domain. Indeed, studies suggest that laminins containing $\gamma 3$ bind $\alpha 6 \beta 1$ integrins in mouse testes (Yan & Cheng, 2006).

In zebrafish, laminin $\gamma 3$ was found at the periphery of the embryo at the dorsal neural plate, horizontal myoseptum, and ventral vessels. Netrin-1 staining identified protein in these same regions, with the exception of the vasculature. However, in *Lamc3* SBMO embryos Netrin-1 was detected throughout, which suggests $\gamma 3$ might be required for the localisation of Netrin-1 to specific regions. Netrins and laminins have been shown to interact in mice (Schneiders *et al.*, 2007). It is possible that $\gamma 3$ binds soluble Netrin-1 at the horizontal myoseptum to form a haptotactic substrate for the local guidance of primary motoneurons. Indeed, this was recently shown to be the mechanism of neuronal guidance in the mouse neural tube (Dominici *et al.*, 2017; Varadarajan *et al.*, 2017). More work is required to determine whether this is the mechanism for $\gamma 3$ function in the zebrafish.

Conclusion

We show that zebrafish parachordal chain development is affected by loss of *Lamc3*, whether mediated by morpholino knockdown or by CRISPR/Cas9 mutagenesis in F0 embryos. We find that muscle pioneer cells are specified and express *netrin-1a* in the absence of *Lamc3*. However, under knockdown conditions the localisation of Netrin-1 protein extends beyond its domain of the horizontal myoseptum, perhaps because it is normally anchored by $\gamma 3$. We also observe abnormal migration and morphology of trunk motoneurons, which might be explained by mis-localisation of Netrin-1. We suggest the parachordal chain phenotype in $\gamma 3$ -deficient embryos is a consequence of the failure of rostral motoneurons to migrate at the horizontal myoseptum.

Data availability

All datasets underlying the results presented in this manuscript are available from OSF: <http://doi.org/10.17605/OSF.IO/C5BKG> (Eve, 2017).

File 1 - MUSCLE alignments of LAMC1, LAMC2 and LAMC3 proteins. Raw data generated from MUSCLE alignments of laminin gamma (LAMC) proteins from *Nematostella vectensis*, *Mus musculus*, *Danio rerio* and *Homo sapiens*.

File 2 - Trimmed alignments of LAMC1, LAMC2 and LAMC3 proteins for phylogenetic tree building. Raw data used for generating phylogenetic trees, gaps and areas of low conservation of the aligned amino acid sequences from File 1 were trimmed by eye.

File 3 - Raw quantitative RT-PCR data (Cp-values). Duplicate raw Cp-values from qPCR analysis of cDNA synthesised from GFP FACS-sorted Tg(*flila:egfp*) transgenic zebrafish. GFP-ve, cells that did not express *GFP*; GFP+ve, *GFP* expressing cells; No RTase, No reverse transcription of RNA control. Dilution curve and negative (water) controls as labelled.

File 4 - Number of intersegmental vessels and parachordal chains at 48 hpf. Counting of vessels in uninjected, standard control morpholino injected, and *Lamc3* splice-blocking morpholino (SBMO) and translation-blocking morpholino (TBMO) injected embryos. Hpf, hours post fertilisation.

File 5 - Number of intersegmental vessels and parachordal chains at 72 hpf. Counting of vessels in uninjected, standard control morpholino injected and *Lamc3* splice-blocking morpholino (SBMO) and translation-blocking morpholino (TBMO) injected Tg(*flila:egfp*) embryos. Hpf, hours post fertilisation.

File 6 - Number of hemisegments with thoracic duct at 5 dpf. Counting of thoracic duct vessels in standard control morpholino injected and *Lamc3* splice-blocking morpholino (SBMO) injected Tg(*kdr1:gfp,prox1a:rfp*) embryos. Dpf, days post fertilisation.

File 7 - Number of HB9 cells at 2 dpf. Counting of HB9 immunostained cells in standard control morpholino injected and *Lamc3* splice-blocking morpholino (SBMO) injected embryos. Dpf, days post fertilisation.

File 8 - Number of caudal and rostral motoneurons at 2 dpf. Counting of caudal and rostral motoneurons in standard control morpholino injected and *Lamc3* splice-blocking morpholino (SBMO) injected Tg(*gfap:gfp*) embryos. Dpf, days post fertilisation.

File 9 - Raw data of Western blot gel used in Figure 4I.

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by the Wellcome Trust [FC001157]; Cancer Research UK [FC001157]; the UK Medical Research Council [FC001157] and Fondation Leducq.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We thank E. Place for cDNA from FACS sorted embryos and for her comments on the manuscript, helpful discussions, guidance, and continued support. We are also grateful to J. Fischer, J. Cayuso, and E. Ober for discussion and use of their transgenic fish lines. Finally we thank the members of the Leducq Fondation Vasculomorph network for their support, discussion and fun.

Supplementary material

Figure S1. Examples of image manipulation from raw data (original images) as labelled.

[Click here to access the data.](#)

Figure S2. Overexpression of mouse *Lamc3* mRNA. (A–C) Anti-LAMC3 immunostaining in the dissected trunks of 24 hpf embryos either uninjected (A), injected with 1 nl of 200 ng/μl of mouse *Lamc3* (mLamc3) mRNA (B) or injected with 1 nl of 400 ng/μl of mouse *Lamc3* mRNA shows increase of antibody staining at the horizontal myoseptum, dorsal plate of the neural tube and cloaca. (D–F) Imaging of the trunk vasculature in *Tg(fli1a:egfp)* 50 hpf embryos either uninjected (D), injected with 1 nl of 200 ng/μl of mouse *Lamc3* mRNA (E) or injected with 1 nl of 400 ng/μl of mouse *Lamc3* mRNA (F). A, anterior; D, dorsal; hpf, hours post fertilisation. Scale bars: 100 μm.

[Click here to access the data.](#)

Figure S3. p53 and *Lamc3* translation blocking morpholino (TBMO) injections. (A) 48 hours post fertilisation (hpf) embryo injected with standard control morpholino. (B) 48 hpf embryo injected with *Lamc3* splice-blocking morpholino (SBMO) without p53 morpholino causes reduced eye size and oedema in the head. (C) *Tg(fli1a:egfp)* embryo at 72 hpf injected with *Lamc3* TBMO and p53 morpholino shows loss of the parachordal chain.

[Click here to access the data.](#)

Figure S4. sgRNA injection does not affect parachordal chain (PAC) development. (A) In 50 hpf *Tg(fli1a:egfp)* embryos injected with 1nl of 12–15 ng/μl of sgRNA1 failure of PAC development (red asterisk) is observed in fewer than 5 hemisegments at the yolk extension per embryo (48/51). (B) A third of embryos injected with sgRNA1 and Cas9 mRNA have perturbed development of the PAC in 5 or more hemisegments at the level of the yolk extension (16/47). A, anterior; D, dorsal; hpf, hours post fertilisation.

[Click here to access the data.](#)

References

- Aumailley M, Bruckner-Tuderman L, Carter WG, *et al.*: **A simplified laminin nomenclature.** *Matrix Biol.* 2005; **24**(5): 326–332.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Baldessari D, Mione M: **How to create the vascular tree? (Latest) help from the zebrafish.** *Pharmacol Ther.* 2008; **118**(2): 206–230.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bernardos RL, Raymond PA: **GFAP transgenic zebrafish.** *Gene Expr Patterns.* 2006; **6**(8): 1007–1013.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bertrand JY, Chi NC, Santoso B, *et al.*: **Haematopoietic stem cells derive directly from aortic endothelium during development.** *Nature.* 2010; **464**(7285): 108–111.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Blagden CS, Currie PD, Ingham PW, *et al.*: **Notochord induction of zebrafish slow muscle mediated by Sonic hedgehog.** *Genes Dev.* 1997; **11**(17): 2163–2175.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Brusés JL: **N-cadherin regulates primary motor axon growth and branching during zebrafish embryonic development.** *J Comp Neurol.* 2011; **519**(9): 1797–815.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Cannon JE, Place ES, Eve AM, *et al.*: **Global analysis of the haematopoietic and endothelial transcriptome during zebrafish development.** *Mech Dev.* 2013; **130**(2–3): 122–131.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Chi NC, Shaw RM, De Val S, *et al.*: **Foxn4 directly regulates *tbx2b* expression and atrioventricular canal formation.** *Genes Dev.* 2008; **22**(6): 734–739.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Covassin L, Amigo JD, Suzuki K, *et al.*: **Global analysis of hematopoietic and vascular endothelial gene expression by tissue specific microarray profiling in zebrafish.** *Dev Biol.* 2006; **299**(2): 551–562.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Dénes V, Witkovsky P, Koch M, *et al.*: **Laminin deficits induce alterations in the development of dopaminergic neurons in the mouse retina.** *Vis Neurosci.* 2007; **24**(4): 549–562.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Dolez M, Nicolas JF, Hirsinger E: **Laminins, via heparan sulfate proteoglycans, participate in zebrafish myotome morphogenesis by modulating the pattern of Bmp responsiveness.** *Development.* 2011; **138**(1): 97–106.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dominici C, Moreno-Bravo JA, Puiggros SR, *et al.*: **Floor-plate-derived netrin-1 is dispensable for commissural axon guidance.** *Nature.* 2017; **545**(7654): 350–354.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Domogatskaya A, Rodin S, Tryggvason K: **Functional Diversity of Laminins.** *Annu Rev Cell Dev Biol.* 2012; **28**: 523–553.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dunworth WP, Cardona-Costa J, Bozkulak EC, *et al.*: **Bone Morphogenetic Protein 2 Signaling Negatively Modulates Lymphatic Development in Vertebrate Embryos.** *Circ Res.* 2014; **114**(1): 56–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Durbeej M, Henry MD, Campbell KP: **Dystroglycan in development and disease.** *Curr Opin Cell Biol.* 1998; **10**(5): 594–601.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Eisen JS, Smith JC: **Controlling morpholino experiments: don't stop making antisense.** *Development.* 2008; **135**(10): 1735–1743.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Eve AMJ: **Knockdown of Laminin gamma-3 (Lamc3) impairs motoneuron guidance in the zebrafish embryo.** 2017.
[Data Source](#)
- Eve AM, Place ES, Smith JC: **Comparison of Zebrafish *tmem88a* mutant and morpholino knockdown phenotypes.** *PLoS One.* 2017; **12**(2): e0172227.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Feldner J, Reimer MM, Schweitzer J, *et al.*: **PlexinA3 restricts spinal exit points and branching of trunk motor nerves in embryonic zebrafish.** *J Neurosci.* 2007; **27**(18): 4978–4983.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gersdorff N, Kohfeldt E, Sasaki T, *et al.*: **Laminin gamma3 chain binds to nidogen and is located in murine basement membranes.** *J Biol Chem.* 2005; **280**(23): 22146–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gnanaguru G, Bachay G, Biswas S, *et al.*: **Laminins containing the β2 and**

$\gamma 3$ chains regulate astrocyte migration and angiogenesis in the retina. *Development*. 2013; **140**(9): 2050–2060.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Hale LA, Fowler DK, Eisen JS: **Netrin signaling breaks the equivalence between two identified zebrafish motoneurons revealing a new role of intermediate targets.** *PLoS One*. 2011; **6**(10): e25841.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Hallmann R, Horn N, Selg M, *et al.*: **Expression and function of laminins in the embryonic and mature vasculature.** *Physiol Rev*. 2005; **85**(3): 979–1000.

[PubMed Abstract](#) | [Publisher Full Text](#)

Herbert SP, Huisken J, Kim TN, *et al.*: **Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation.** *Science*. 2009; **326**(5950): 294–298.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Hogan BM, Bos FL, Bussmann J, *et al.*: **Ccbe1 is required for embryonic lymphangiogenesis and venous sprouting.** *Nat Genet*. 2009; **41**(4): 396–398.

[PubMed Abstract](#) | [Publisher Full Text](#)

Höpker VH, Shewan D, Tessier-Lavigne M, *et al.*: **Growth-cone attraction to netrin-1 is converted to repulsion by laminin-1.** *Nature*. 1999; **401**(6748): 69–73.

[PubMed Abstract](#) | [Publisher Full Text](#)

Hwang WY, Fu Y, Reyon D, *et al.*: **Efficient genome editing in zebrafish using a CRISPR-Cas system.** *Nat Biotechnol*. 2013; **31**(3): 227–229.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Ido H, Ito S, Taniguchi Y, *et al.*: **Laminin isoforms containing the gamma3 chain are unable to bind to integrins due to the absence of the glutamic acid residue conserved in the C-terminal regions of the gamma1 and gamma2 chains.** *J Biol Chem*. 2008; **283**(42): 28149–57.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Jao LE, Wenthe SR, Chen W: **Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system.** *Proc Natl Acad Sci U S A*. 2013; **110**(34): 13904–9.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Jing L, Zon LI: **Zebrafish as a model for normal and malignant hematopoiesis.** *Dis Model Mech*. 2011; **4**(4): 433–438.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Kearse M, Moir R, Wilson A, *et al.*: **Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data.** *Bioinformatics*. 2012; **28**(12): 1647–1649.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Kim JG, Bae SJ, Lee HS, *et al.*: **Claudin5a is required for proper inflation of Kupffer's vesicle lumen and organ laterality.** *PLoS One*. 2017; **12**(8): e0182047.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Kimmel CB, Ballard WW, Kimmel SR, *et al.*: **Stages of Embryonic development of the zebrafish.** *Dev Dyn*. 1995; **203**(3): 253–310.

[PubMed Abstract](#) | [Publisher Full Text](#)

Kitajewski J: **Endothelial laminins underlie the tip cell microenvironment.** *EMBO Rep*. 2011; **12**(11): 1087–8.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Koch M, Olson PF, Albus A, *et al.*: **Characterization and expression of the laminin gamma3 chain: a novel, non-basement membrane-associated, laminin chain.** *J Cell Biol*. 1999; **145**(3): 605–618.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Kok FO, Shin M, Ni CW, *et al.*: **Reverse genetic screening reveals poor correlation between morpholino-induced and mutant phenotypes in zebrafish.** *Dev Cell*. 2015; **32**(1): 97–108.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Lauderdale JD, Davis NM, Kuwada JY: **Axon tracts correlate with netrin-1a expression in the zebrafish embryo.** *Mol Cell Neurosci*. 1997; **9**(4): 293–313.

[PubMed Abstract](#) | [Publisher Full Text](#)

Lawson ND, Weinstein BM: **In vivo imaging of embryonic vascular development using transgenic zebrafish.** *Dev Biol*. 2002; **248**(2): 307–318.

[PubMed Abstract](#) | [Publisher Full Text](#)

Li YN, Radner S, French MM, *et al.*: **The $\gamma 3$ chain of laminin is widely but differentially expressed in murine basement membranes: expression and functional studies.** *Matrix Biol*. 2012; **31**(2): 120–134.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Libby RT, Champlaud MF, Claudepierre T, *et al.*: **Laminin expression in adult and developing retinae: evidence of two novel CNS laminins.** *J Neurosci*. 2000; **20**(17): 6517–6528.

[PubMed Abstract](#) | [Free Full Text](#)

Lim AH, Suli A, Yaniv K, *et al.*: **Motoneurons are essential for vascular pathfinding.** *Development*. 2011; **138**(17): 3847–3857.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Maurya AK, Ben J, Zhao Z, *et al.*: **Positive and Negative Regulation of Gli Activity by Klf7 in the Zebrafish Embryo.** *PLoS Genet*. 2013; **9**(12): e1003955.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Miller MA, Pfeiffer W, Schwartz T: **Creating the CIPRES Science Gateway for inference of large phylogenetic trees.** *2010 GATEWAY Comput Environ Work GCE 2010*. 2010.

[Publisher Full Text](#)

Miner JH, Cunningham J, Sanes JR: **Roles for laminin in embryogenesis: Exencephaly, syndactyly, and placental pathology in mice lacking the laminin alpha5 chain.** *J Cell Biol*. 1998; **143**(6): 1713–1723.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Navankasattusas S, Whitehead KJ, Suli A, *et al.*: **The netrin receptor UNC5B promotes angiogenesis in specific vascular beds.** *Development*. 2008; **135**(4): 659–667.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Novodvorsky P, Watson O, Gray C, *et al.*: **klf2a^{sh317} Mutant Zebrafish Do Not Recapitulate Morpholino-Induced Vascular and Haematopoietic Phenotypes.** *PLoS One*. 2015; **10**(10): e0141611.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Nusslein-Volhard C, Dahm R: **Zebrafish: a practical approach.** Nusslein-Volhard 2002: New York: Oxford University Press, 2002.

[Reference Source](#)

Odenthal J, Haffter P, Vogelsan E, *et al.*: **Mutations affecting the formation of the notochord in the zebrafish, Danio rerio.** *Development*. 1996; **123**: 103–115.

[PubMed Abstract](#)

Okuda KS, Astin JW, Misa JP, *et al.*: **lyve1 expression reveals novel lymphatic vessels and new mechanisms for lymphatic vessel development in zebrafish.** *Development*. 2012; **139**(13): 2381–2391.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Park KW, Crouse D, Lee M, *et al.*: **The axonal attractant Netrin-1 is an angiogenic factor.** *Proc Natl Acad Sci U S A*. 2004; **101**(46): 16210–16215.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Parsons MJ, Pollard SM, Saúde L, *et al.*: **Zebrafish mutants identify an essential role for laminins in notochord formation.** *Development*. 2002; **129**(13): 3137–3146.

[PubMed Abstract](#)

Paulus JD, Halloran MC: **Zebrafish bashful/laminin-alpha 1 mutants exhibit multiple axon guidance defects.** *Dev Dyn*. 2006; **235**(1): 213–224.

[PubMed Abstract](#) | [Publisher Full Text](#)

Pinzón-Duarte G, Daly G, Li YN, *et al.*: **Defective formation of the inner limiting membrane in laminin beta2- and gamma3-null mice produces retinal dysplasia.** *Invest Ophthalmol Vis Sci*. 2010; **51**(3): 1773–1782.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Place ES, Smith JC: **Zebrafish atoh8 mutants do not recapitulate morpholino phenotypes.** *PLoS One*. 2017; **12**(2): e0171143.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Pollard SM, Parsons MJ, Kamei M, *et al.*: **Essential and overlapping roles for laminin alpha chains in notochord and blood vessel formation.** *Dev Biol*. 2006; **289**(1): 64–76.

[PubMed Abstract](#) | [Publisher Full Text](#)

Rambaut A: **FigTree v1.4.3.** 2009.

Ratcliffe EM, D'Autréaux F, Gershon MD: **Laminin terminates the Netrin/DCC mediated attraction of vagal sensory axons.** *Dev Neurobiol*. 2008; **68**(7): 960–71.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Relan NK, Yang Y, Beqaj S, *et al.*: **Cell elongation induces laminin alpha2 chain expression in mouse embryonic mesenchymal cells: role in visceral myogenesis.** *J Cell Biol*. 1999; **147**(6): 1341–1350.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Rossi A, Kontarakis Z, Gerri C, *et al.*: **Genetic compensation induced by deleterious mutations but not gene knockdowns.** *Nature*. 2015; **524**(7564): 230–3.

[PubMed Abstract](#) | [Publisher Full Text](#)

Sander JD, Maeder ML, Reyon D, *et al.*: **ZIFIT (Zinc Finger Targeter): An updated zinc finger engineering tool.** *Nucleic Acids Res*. 2010; **38**(Web Server issue): W462–468.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Schneiders FI, Maertens B, Böse K, *et al.*: **Binding of netrin-4 to laminin short arms regulates basement membrane assembly.** *J Biol Chem*. 2007; **282**(33): 23750–23758.

[PubMed Abstract](#) | [Publisher Full Text](#)

Sharma KR, Heckler K, Stoll SJ, *et al.*: **ELMO1 protects renal structure and ultrafiltration in kidney development and under diabetic conditions.** *Sci Rep*. 2016; **6**: 37172.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Stainier DY, Fishman MC: **The zebrafish as a model system to study cardiovascular development.** *Trends Cardiovasc Med*. 1994; **4**(5): 207–212.

[PubMed Abstract](#) | [Publisher Full Text](#)

Stainier DY, Weinstein BM, Detrich HW 3rd, *et al.*: **cloche, an early acting zebrafish gene, is required by both the endothelial and hematopoietic lineages.** *Development*. 1995; **121**(10): 3141–3150.

[PubMed Abstract](#)

Stainier D, Raz E, Lawson ND, *et al.*: **Guidelines for morpholino use in zebrafish.** *PLoS Genet*. 2017; **13**(10): e1007000.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Stenzel D, Franco CA, Estrach S, *et al.*: **Endothelial basement membrane limits tip cell formation by inducing Dll4/Notch signalling in vivo.** *EMBO Rep*. 2011; **12**(11): 1135–43.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Sumanas S, Joriniak T, Lin S: **Identification of novel vascular endothelial-specific**

genes by the microarray analysis of the zebrafish *cloche* mutants. *Blood*. 2005; **106**(2): 534–541.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Swift MR, Weinstein BM: Arterial-venous specification during development. *Circ Res*. 2009; **104**(5): 576–88.

[PubMed Abstract](#) | [Publisher Full Text](#)

Sztal T, Berger S, Currie PD, *et al.*: Characterization of the laminin gene family and evolution in zebrafish. *Dev Dyn*. 2011; **240**(2): 422–431.

[PubMed Abstract](#) | [Publisher Full Text](#)

Tanabe Y, William C, Jessell TM: Specification of motor neuron identity by the MNR2 homeodomain protein. *Cell*. 1998; **95**(1): 67–80.

[PubMed Abstract](#) | [Publisher Full Text](#)

Thisse C, Thisse B: High-resolution *in situ* hybridization to whole-mount zebrafish embryos. *Nat Protoc*. 2008; **3**(1): 59–69.

[PubMed Abstract](#) | [Publisher Full Text](#)

Varadarajan SG, Kong JH, Phan KD, *et al.*: Netrin1 Produced by Neural

Progenitors, Not Floor Plate Cells, Is Required for Axon Guidance in the Spinal Cord. *Neuron*. 2017; **94**(4): 790–799.e3.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Waterhouse AM, Procter JB, Martin DM, *et al.*: Jalview Version 2—a multiple sequence alignment editor and analysis workbench. *Bioinformatics*. 2009; **25**(9): 1189–1191.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Wiley DM, Kim JD, Hao J, *et al.*: Distinct signalling pathways regulate sprouting angiogenesis from the dorsal aorta and the axial vein. *Nat Cell Biol*. 2011; **13**(6): 686–692.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Yan HH, Cheng CY: Laminin alpha 3 forms a complex with beta3 and gamma3 chains that serves as the ligand for alpha 6beta1-integrin at the apical ectoplasmic specialization in adult rat testes. *J Biol Chem*. 2006; **281**(25): 17286–17303.

[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:



Version 1

Reviewer Report 26 January 2018

<https://doi.org/10.21956/wellcomeopenres.13423.r29423>

© 2018 Hawkins T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Thomas A. Hawkins 

Division of Biosciences, Cell and Developmental Biology, University College London, London, UK

This is a well constructed and clearly written manuscript. The authors present a straightforward story of a knockdown of laminin 3 (Lamc3) and the consequence of this on parachordal chain and motoneuron development. The knockdown of Lamc3 was achieved using morpholino oligonucleotide injection that was validated by transient, mosaic genetic lesions in F0 embryos using CRISPR/Cas9. They indicate that upon reduced lamc3 expression, the parachordal chain is lost and that motoneuron morphology is perturbed; the former defect is suggested to be the consequence of the latter, consistent with earlier findings. Abnormal midline development evidenced by altered netrin expression and changes in prox1a transgene expression as a consequence of the loss of lamc3 is cited as a probable cause of the defects.

The experimental procedures admirably well presented: they are thoroughly described, and they seem to have been carried out carefully. The data presented are of a high quality. The authors are sensibly cautious and measured in the language employed to describe their results and to conclude from them. Their findings do throw up several further questions and many of these are discussed by the authors. I might normally ask for more experiments to develop the study more but I recognise that the reviewer guidelines are limited to an analysis of the quality of the work presented; discussion of the further questions would seem to suffice in this context. Nevertheless, I do have a few reservations about the study, as it is presented, these can probably be addressed through adjustment of the manuscript. The main issues are listed below, followed by some smaller items that would improve/correct the manuscript prior to formal publication.

Larger issues

1. Because the study heavily relies upon morpholino use, it is imperative to carefully validate the efficacy of the reagents employed. The authors employ several approaches to this problem, including the use of both splice- and translation-blocking morpholinos, immunohistochemistry against the target protein as well as the replication of the findings using transient CRISPR/Cas9 injection. This is good and refreshing when compared with other published data employing morpholinos. I believe the specificity and efficacy of the morpholino employed is reasonably sure.

However, I was a bit surprised to see that the authors gave up attempting the generation of a full mutant line after apparently only attempting to raise 72 F0 embryos/larvae with only 12 making it to adulthood for genomic testing. (As an aside here the authors do not make clear from what tissue they tested the 12 adults, presumably sample embryos from crosses of the individuals were used? The germ line is obviously the crucial place to test for a heritable mutation. This should be clarified). With the apparently reliable restriction digest assay that the authors have already generated I would have thought it were feasible to either titrate down the dose of the Cas9/sgRNA injections sufficiently, or use the less efficient sgRNA so that there was less mutation load to allow more fish to survive to adulthood for germ line genomic lesion screening. This is certainly a time-consuming undertaking because of generation time, and that may be the problem here but the authors should be honest about that. The morpholino data is certainly convincing as it stands but, as acknowledged by the authors in the discussion, consensus in the community is that bona fide genetic mutants are a 'gold standard' for examination of gene function, particularly also in concert with morpholino use. I feel that the presented reasons for abandoning efforts to obtain a *lamc3* mutant are not really sufficient. I recommend a change to this section to acknowledge it may be possible in the future to generate a mutant using the same reagents employed for 'morpholino validation' here.

2. It is not clear whether the authors were able to correlate more severe genetic lesions using CRISPR/Cas9 and sgRNAs with more severe PAC defects. It seems logical to me that this would be done but the two results are presented separately. Was this carried out? Also, in other studies employing F0 mutagenesis, experimenters have multiplexed their sgRNAs to increase the chance of lesion. Did the authors try this approach?
3. In Fig.4G' there is an abrupt drop off in the NTN1 staining on the left hand side of the sectioned embryo, when passing from dorsal to ventral there is almost a line apparent, below which the expression is much lower compared to the right hand side. What is the cause of this? Was it consistently seen? Perhaps it is a sectioning artifact? Despite this it is clear that the morphant (Panel H') staining is more extensive, the difference between sides in the Std control section is something that stands out. Please comment on this.

Smaller issues

1. A little more detail on the qRT-PCR experiment would be good eg. How was the FACs undertaken? How was the RNA isolated? Were the primer efficiencies determined? Are the n numbers in the panel Fig1D replications of the whole experiment (FACs sorting and qRT-PCR) or just the qRT-PCR? I realise it is a negative result but the detail helps with interpretation.
2. In the methods section, under the probe synthesis and *in situ* hybridisation heading, the manuscript states that the T7 promoter sequence is underlined and SP6 sequence is in italics, neither can be seen in the primer sequences as presented in the version I see online and in PDF.
3. Figure 3 issues: a) The n-numbers for the data in panel E would be useful to present in the panel or at least in the legend. I can see they are in the body but it is much easier for the reader to see them either in legend or panel itself; b) In Fig 3J the blue box above the gel image says "Surviving F0 SG RNA embryos ..." where the legend states *adult* fish; c) The ordering of the panel labelling in fig. 3 is rather odd: Panels A-G are labelled left to right by row and H-J are by column, it makes it hard to read; d) The picture of the three embryos dorsally mounted in the bottom right of figure 3 does not have a panel label or a corresponding legend; e) In my opinion, the "U" in Panel G that denotes undigested would be better described in the section of the legend about this panel rather than at the end of the legend; f) There is no "U" sample in panel H, why? This is a different assay and it would be useful for interpretation.

4. I believe that the results section entitled “Lamc3 is required for parachordal chain (PAC) formation” was intended to go after the “Lamc3 is required for parachordal chain (PAC) formation”. It seems like the more logical order. This is especially true regarding the p53 MO use. The order it is written currently it is ambiguous whether the experiments described in the earlier section employed co-injection of p53 MO or not. I suspect an editing error but, either way, the authors should make clear which experiments employed p53 MO in addition to the various other morpholinos (including Std control).

If the authors are able to address the points above I would be happy for the paper to be formally published. As I hope is clear, the changes are mainly possible to be dealt with through changes in the text. Some of the points I raise are open to debate and I'm happy to engage in this, if necessary.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 24 January 2018

<https://doi.org/10.21956/wellcomeopenres.13423.r29476>

© 2018 Facchinello N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Nicola Facchinello 

Department of Biology, University of Padova, Padova, Italy

In this paper, the Authors used a morpholino and CRISPR/Cas9 approach and they find a role of laminin $\gamma 3$ in motoneuron guidance. The experiments are technically sound and the results are clear. The images are of high quality and the quantification data are well-described, including numbers of animals and numbers of experiments. The manuscript is well written and may be recommended for indexing.

For revision, the following changes are recommended:

Fig1 (Panel D) Were sufficient animals analysed to conclude that no difference exists? It would be interesting if the authors presented a double IF to show if there is a colocalization of Lamc3 (red) and fli1a (anti-GFP) in some vessels.

Fig2. To assess the morpholino efficacy, lam3c specific RT-PCR reactions could be performed on RNA populations or check the decrease of protein level by western blot?

Did you try also a mismatch MO instead of std control?

Fig3 (Panel A) Did you check for sgRNA1 the decrease of mRNA or protein level for Lam3c in the mutant with the phenotype?

A suggestion could be the genotyping of mutations in F0 using heteroduplex mobility assay (HMA)¹. In this way you can identify some mutation that could not be identified by digestion. To try to obtained a stable line in the CRISPR/Cas9 approach, you can try to decrease the concentration and nanoliters inject of sgRNA1 due to its toxicity or too high efficiency.

References

1. Zhu X, Xu Y, Yu S, Lu L, Ding M, Cheng J, Song G, Gao X, Yao L, Fan D, Meng S, Zhang X, Hu S, Tian Y: An efficient genotyping method for genome-modified animals and human cells generated with CRISPR/Cas9 system. *Sci Rep.* 2014; **4**: 6420 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 22 January 2018

<https://doi.org/10.21956/wellcomeopenres.13423.r29478>

© 2018 Liu D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Dong Liu** 

Co-Innovation Center of Neuroregeneration, Jiangsu Key Laboratory of Neuroregeneration, Nantong University, Nantong, China

The authors provided with evidences that *lamc3* was enriched in endothelial cells as a regulator of retinal neuronal guidance. However, it has not been investigated on zebrafish model. The authors performed *Lamc3* knockdown and knockout using Mo and CRISPR/Cas9 approaches during zebrafish development. It was revealed that *Lamc3* deficiency disturbed the formation of the PAC, the thoracic duct, and axonal guidance of rostral primary moto neuron which might be caused by up-regulation of *netrin-1a* in the neural tube, but not sprouting of the cardinal vein. The manuscript was well written and the figures were well presented. However, I have some questions that need to be addressed:

1. In the results section, the authors discribed that LAMC3 is most closely related to LAMC1. Whether LAMC1 were closer to the clade of LAMC2 based on Fig.1B. ?
2. In Fig.1G-H, it will be more convincing to colocalize the expression of LAMC3 and endothelial cell specific gene, such as *kdrl*, using immunostaining or the transgenic lines which express florescent proteins in endothelial cells.
3. In the Figure1, Is the legend (I) indicating the panel (H')?
4. The content of figure S4 was similar with figure3B-D. What is the difference between them?
5. The authors showed that *lamc3* loss-of-function impaired the formation of parachordal chain (PAC) and thoracic duct. To confirm the phenotype was caused specifically by loss of *lamc3*, I suggest the authors to examine whether *lamc3* mRNA could rescue the phenotypes in morphants and mutants.
6. Since the impaired blood flow affects the formation of parachordal chain (PAC) and thoracic duct in zebrafish. Whether the phenotype of *lamc3* deficient embryos was caused by blood flow defect as a secondary effect needs to be seriously checked.
7. line is often employed in the study of astrocytes. Why did the authors chose the *Tg(gfap:gfp)* line to study motoneuron development instead of *Tg(mnx1:EGFP)*?
8. Motoneurons are essential for vascular pathfinding. Were the parachordal chain (PAC) defects were caused by primary motoneurons malformation?
9. In figure 4F, expression domain of *netrin-1a* was increased in the neural tube, the *netrin1a* signals in horizontal myoseptum and the whole embryo were stronger too. In contrast, the authors found that the *netrin-1* protein was reduced in all *Lamc3* knockdown embryos at the level of the horizontal myoseptum compared with controls, the authors should give some interpretation.
10. Results that *netrin* expression was affected by LAMC3 knockdown are interesting. I suggest the authors add the relevant discussion, for example the potential molecular mechanism.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 13 December 2017

<https://doi.org/10.21956/wellcomeopenres.13423.r28075>

© 2017 Chico T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Timothy J.A. Chico

Department of Infection, Immunity & Cardiovascular Disease, Medical School, The Bateson Centre for Lifecourse Biology, University of Sheffield, Sheffield, UK

SUMMARY

I enjoyed reading this paper, which was conducted technically well and presented in a very accessible and thorough manner. The authors are sensibly cautious about the conclusions that they draw. I wholeheartedly believe that the huge amount of unpublished morpholino data, were it available to the community, would be of great value even with the difficulty in being certain that all the described effects are specific so am very keen that this paper, and the hundreds like it that I suspect could be written, be disseminated.

I make some general comments below, but the main point that I think should be kept in mind when interpreting this paper is that non-specific effects on cardiac output induced by the morpholino or the CRISPR gRNA would be expected to induce the same reduction in lymphatic formation; unless the authors revise the manuscript to include an assessment of cardiac output and blood flow then I would be a little uncomfortable assuming that these effects have much to do with LAMC3 directly. It would be reasonable however, to acknowledge this and other potential confounders a little more clearly in the results and discussion if it is not possible at this stage to examine the effects of the genetic manipulations on blood flow.

The immunostaining against Laminin 3 (Fig 1) is nice but without more validation that it binds selectively to zebrafish LAMC3 (such as a western blot) it is hard to be certain that the immunostaining is specific to this isoform of laminin, especially with a cross-species antibody. The overexpression study in the supplemental data does show that there is increased antibody binding to mouse LAMC3 when overexpressed but does not rule out it binding to other laminins or non-specifically, nor does it confirm it binds to zebrafish LAMC3. I would therefore consider the protein expression data to be likely correct but not completely validated. However, the reduction of staining in the LAMC3 morphants makes it likely that the antibody binds to the MO target; it just cannot be concluded that it doesn't bind to anything else!

Figure 2 shows nicely that the LAMC3 morpholino prevents lymphatic formation. However, a similar effect is seen if blood flow is prevented in embryos, for example by troponin knockdown. To be certain that this does not explain the observed phenotype, it would be necessary to show that the morpholino does not alter cardiac output and blood flow in the dose used.

The CRISPR/Cas9 methods indicate that some embryos were injected with gRNAs alone (which is an appropriate control) but the results don't show these data; they only show Cas9 alone as a control. My own group has found that some gRNAs at high doses do induce toxicity and these data should be shown or discussed. I'm not convinced that the different effects of the second guide RNA exclude off target toxicity from a different guide; we see varying effects with different guide sequences.

Although the LAMC3 crisprants show similar defects in lymphatic development as the morphants, again this could be secondary to alterations in blood flow which would need to be examined to exclude such a confounding effect.

The authors do seem to have encountered a problem with the CRISPR/Cas9 system, in that they have found a really efficient guideRNA that cuts bi-allelically and so induces a lethal phenotype that means a heterozygous founder cannot be identified. It would have made more sense to raise the embryos injected with the second, less efficient guide as this does seem to induce mosaic/heterozygous mutations more compatible with finding a founder adult.

The alteration of netrin expression induced by LAMC3 knockdown is interesting, but would be strengthened by quantification (in addition to the usual 12/13 type annotation which cannot be confirmed by a reviewer). For example, if the expression domains are quantified blindly, is there a statistically significant alteration? It seems this would be very achievable and would make the conclusions far more solid. In passing, no mention of blinding during analysis is made in the methods, and it would be important to know if when the quantification was performed in for example Figure 2 that the observer was blinded to group allocation.

Minor points

Table 1 refers to concentrations of morpholinos but these are doses per embryo.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

No

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: I examined the PhD thesis and recommended award of the PhD to the first author.

Reviewer Expertise: Zebrafish cardiovascular formation and genetic manipulation

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
